Hospital
Keck Medical Center of Usc
Keck Medical Center of Usc was paid $44.98M by Medicaid between Jan 2021 and Dec 2024, across 330 billing codes. Its largest line is 93306, Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete — 7.4% of everything it billed.
33Billing provider infoKECK MEDICAL CENTER OF USC
LOS ANGELES, CA 90033
LOS ANGELES, CA 90033
33aNPI1013514199assigned 10/02/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$44.98M
24GClaims409,834
24DCodes billed330
24AFirst – last monthJan 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#69 of 410
Median peer was paid$6.90M
This provider vs. median6.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 59,772 | $5.68M | |
| 2022 | 101,715 | $10.93M | |
| 2023 | 127,891 | $16.39M | |
| 2024incomplete | 120,456 | $11.98M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 7.4% | 3,482 | 3,366 | $3.33M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 5.4% | 1,650 | 1,642 | $2.42M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.0% | 39,935 | 34,145 | $2.24M |
| 0360 | 4.0% | 851 | 677 | $1.80M | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 3.6% | 1,331 | 1,305 | $1.64M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.9% | 4,237 | 4,052 | $1.30M |
| 80053 | Comprehensive metabolic panel | 2.7% | 14,403 | 11,116 | $1.23M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 1,371 | 1,359 | $1.20M |
| 74178 | 2.5% | 627 | 611 | $1.12M | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 3,274 | 2,307 | $1.06M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.3% | 881 | 845 | $1.03M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 2.0% | 1,897 | 1,877 | $920K |
318 more codes
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.0% | 884 | $885K |
| 0250 | 1.5% | 5,123 | $695K | |
| 0760 | 1.5% | 6,827 | $674K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 1,736 | $661K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.4% | 171 | $645K |
| 0710 | 1.4% | 1,604 | $630K | |
| 71250 | 1.4% | 1,450 | $616K | |
| 74183 | 1.3% | 524 | $598K | |
| 93017 | 1.3% | 1,254 | $577K | |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 3,011 | $570K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 548 | $559K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 1.2% | 677 | $529K |
| 82962 | 1.1% | 3,877 | $502K | |
| 72197 | 1.1% | 531 | $495K | |
| 0270 | 1.1% | 2,295 | $482K | |
| 99199 | Unlisted special service, procedure or report | <1% | 2,816 | $442K |
| 0272 | <1% | 3,233 | $425K | |
| 74174 | <1% | 673 | $422K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,687 | $383K |
| 80197 | <1% | 8,921 | $382K | |
| 0370 | <1% | 2,090 | $378K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,631 | $377K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,443 | $327K |
| 93975 | <1% | 1,276 | $318K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,940 | $307K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,568 | $303K |
| Q3014 | Telehealth originating site facility fee | <1% | 15,272 | $303K |
| 86850 | <1% | 3,833 | $284K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 304 | $281K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 799 | $273K |
| 83735 | <1% | 11,135 | $256K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 471 | $252K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,761 | $242K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,524 | $235K |
| 99070 | <1% | 409 | $231K | |
| 86900 | <1% | 4,551 | $226K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 666 | $217K |
| 85610 | <1% | 5,069 | $207K | |
| J0485 | Injection, belatacept, 1 mg | <1% | 316 | $205K |
| 94010 | <1% | 1,838 | $204K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,003 | $192K |
| 86832 | <1% | 2,715 | $185K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,356 | $178K |
| 0510 | <1% | 15,832 | $178K | |
| 86833 | <1% | 2,719 | $171K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,094 | $169K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,372 | $165K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,699 | $162K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 322 | $159K |
| 82565 | <1% | 1,444 | $156K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 668 | $144K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 632 | $143K |
| 87497 | <1% | 3,617 | $142K | |
| 94618 | <1% | 688 | $139K | |
| 93356 | <1% | 625 | $136K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 370 | $128K |
| 94726 | <1% | 741 | $126K | |
| 92134 | <1% | 2,448 | $125K | |
| 80069 | <1% | 3,024 | $122K | |
| 82040 | <1% | 408 | $122K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 210 | $121K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,769 | $121K |
| 86481 | <1% | 952 | $118K | |
| 86920 | <1% | 465 | $114K | |
| 81001 | <1% | 6,691 | $114K | |
| 92083 | <1% | 1,364 | $112K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 204 | $109K |
| J0897 | Injection, denosumab, 1 mg | <1% | 140 | $109K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 398 | $107K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 49 | $101K |
| 72110 | <1% | 529 | $97K | |
| 73564 | <1% | 849 | $92K | |
| 86901 | <1% | 4,473 | $92K | |
| 93880 | <1% | 294 | $90K | |
| 93970 | <1% | 333 | $90K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 223 | $90K |
| 93350 | <1% | 67 | $89K | |
| 73630 | <1% | 509 | $89K | |
| 94729 | <1% | 724 | $87K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,609 | $82K |
| 84100 | <1% | 6,840 | $82K | |
| 92557 | <1% | 785 | $82K | |
| 0361 | <1% | 297 | $79K | |
| 88342 | <1% | 400 | $78K | |
| 83880 | <1% | 2,291 | $78K | |
| 96415 | <1% | 873 | $77K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 424 | $76K |
| 71045 | Radiologic examination, chest; single view | <1% | 809 | $72K |
| 91200 | <1% | 418 | $72K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,678 | $71K |
| 73030 | <1% | 635 | $69K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 429 | $68K |
| 94060 | <1% | 245 | $66K | |
| 72141 | <1% | 108 | $64K | |
| 92133 | <1% | 1,045 | $64K | |
| 31231 | <1% | 463 | $63K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,828 | $63K |
| 87799 | <1% | 2,420 | $60K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 96 | $58K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,063 | $55K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 734 | $53K |
| J3490 | Unclassified drugs | <1% | 943 | $50K |
| 76776 | <1% | 262 | $50K | |
| A9270 | Non-covered item or service | <1% | 2,771 | $49K |
| 31237 | <1% | 43 | $48K | |
| 74230 | <1% | 272 | $48K | |
| 72100 | <1% | 354 | $47K | |
| 93325 | <1% | 229 | $46K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 666 | $45K |
| 73562 | <1% | 607 | $45K | |
| 84156 | <1% | 4,316 | $44K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 101 | $43K |
| 73502 | <1% | 510 | $43K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 17 | $41K |
| 76770 | <1% | 298 | $40K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,646 | $39K |
| 87070 | <1% | 834 | $39K | |
| 85730 | <1% | 2,658 | $38K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,419 | $37K |
| 80061 | Lipid panel | <1% | 1,908 | $37K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,100 | $36K |
| 93296 | <1% | 836 | $35K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 68 | $35K |
| 86828 | <1% | 524 | $34K | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 46 | $33K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,755 | $33K |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 208 | $32K |
| 81376 | <1% | 184 | $32K | |
| 82570 | <1% | 4,619 | $32K | |
| 99221 | <1% | 1,076 | $31K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,501 | $30K |
| 86803 | <1% | 1,231 | $30K | |
| 86592 | <1% | 1,167 | $30K | |
| 92504 | <1% | 1,032 | $29K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,544 | $28K |
| 93922 | <1% | 228 | $28K | |
| 87150 | <1% | 895 | $26K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,883 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,884 | $26K |
| 86704 | <1% | 1,208 | $26K | |
| 87081 | <1% | 1,763 | $23K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 646 | $23K |
| 73610 | <1% | 275 | $22K | |
| 86480 | <1% | 204 | $21K | |
| 87186 | <1% | 730 | $21K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,613 | $21K |
| 77073 | <1% | 360 | $21K | |
| 87077 | <1% | 1,152 | $20K | |
| 85027 | <1% | 2,403 | $20K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 887 | $19K |
| 43235 | <1% | 12 | $19K | |
| 86140 | <1% | 1,041 | $19K | |
| 87517 | <1% | 456 | $19K | |
| 87205 | <1% | 790 | $19K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 683 | $18K |
| 31575 | <1% | 193 | $18K | |
| 73560 | <1% | 253 | $18K | |
| 77080 | <1% | 213 | $18K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 983 | $17K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 789 | $17K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 664 | $17K |
| 0255 | <1% | 246 | $17K | |
| 92250 | <1% | 435 | $17K | |
| 93454 | <1% | 15 | $17K | |
| Z7500 | <1% | 471 | $16K | |
| 87340 | <1% | 1,314 | $16K | |
| 83970 | <1% | 541 | $16K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 656 | $15K |
| 84153 | <1% | 719 | $15K | |
| 81025 | <1% | 620 | $15K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 524 | $15K |
| 97597 | <1% | 456 | $14K | |
| 72050 | <1% | 136 | $14K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 680 | $14K |
| 87536 | <1% | 137 | $14K | |
| 80076 | <1% | 221 | $13K | |
| 73552 | <1% | 179 | $13K | |
| 81373 | <1% | 153 | $13K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 90 | $13K |
| 82550 | <1% | 457 | $12K | |
| 73522 | <1% | 131 | $12K | |
| 83540 | <1% | 1,088 | $12K | |
| 83550 | <1% | 1,061 | $12K | |
| 87522 | Neg quan hep c or qual rna | <1% | 236 | $12K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 13 | $11K |
| 82728 | <1% | 767 | $11K | |
| 86635 | <1% | 977 | $11K | |
| 88307 | <1% | 52 | $9K | |
| 86317 | <1% | 1,276 | $8K | |
| 73700 | <1% | 13 | $8K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 146 | $8K |
| 93925 | <1% | 39 | $7K | |
| 84439 | <1% | 526 | $7K | |
| 82105 | <1% | 624 | $7K | |
| 93321 | <1% | 42 | $7K | |
| J3590 | Unclassified biologics | <1% | 96 | $7K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 189 | $7K |
| 87210 | <1% | 206 | $7K | |
| 92025 | <1% | 167 | $7K | |
| 0761 | <1% | 312 | $7K | |
| 93308 | <1% | 17 | $7K | |
| 82107 | <1% | 319 | $6K | |
| 82803 | <1% | 27 | $6K | |
| 83615 | <1% | 530 | $6K | |
| 83951 | <1% | 219 | $6K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 107 | $6K |
| 93246 | <1% | 103 | $6K | |
| 90677 | <1% | 26 | $6K | |
| 80180 | <1% | 862 | $6K | |
| 87102 | <1% | 205 | $6K | |
| 93280 | <1% | 146 | $6K | |
| 85652 | <1% | 1,007 | $6K | |
| 0300 | <1% | 151 | $6K | |
| 73590 | <1% | 68 | $6K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,031 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 169 | $5K |
| 90662 | <1% | 147 | $5K | |
| 70486 | <1% | 12 | $5K | |
| 76536 | <1% | 45 | $5K | |
| 0271 | <1% | 333 | $5K | |
| 72040 | <1% | 39 | $4K | |
| 73221 | <1% | 12 | $4K | |
| C1769 | Guide wire | <1% | 98 | $4K |
| 74240 | <1% | 27 | $4K | |
| 86665 | <1% | 946 | $4K | |
| 88304 | <1% | 75 | $4K | |
| 82607 | <1% | 392 | $4K | |
| 92567 | <1% | 108 | $4K | |
| 83605 | <1% | 134 | $4K | |
| 93283 | <1% | 37 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 53 | $3K |
| 84484 | <1% | 140 | $3K | |
| 82784 | <1% | 326 | $3K | |
| 88313 | <1% | 26 | $3K | |
| 31579 | <1% | 12 | $3K | |
| 72082 | <1% | 14 | $3K | |
| 82610 | <1% | 464 | $3K | |
| X3908 | <1% | 96 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 179 | $3K |
| 86644 | <1% | 948 | $3K | |
| 87040 | <1% | 40 | $3K | |
| 0420 | <1% | 15 | $2K | |
| 87015 | <1% | 134 | $2K | |
| 93971 | <1% | 13 | $2K | |
| 93976 | <1% | 14 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 198 | $2K |
| 92588 | <1% | 13 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 13 | $2K |
| 86645 | <1% | 744 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 31 | $2K |
| 96367 | <1% | 36 | $2K | |
| 86790 | <1% | 145 | $2K | |
| 73130 | <1% | 24 | $1K | |
| 82746 | <1% | 135 | $1K | |
| A4649 | Surgical supply; miscellaneous | <1% | 138 | $1K |
| 85018 | <1% | 28 | $1K | |
| 86141 | <1% | 281 | $1K | |
| 93926 | <1% | 14 | $1K | |
| 76512 | <1% | 39 | $1K | |
| 88341 | <1% | 13 | $1K | |
| 92526 | <1% | 44 | $1K | |
| 72170 | <1% | 14 | $1K | |
| 97162 | <1% | 12 | $1K | |
| 90686 | <1% | 75 | $1K | |
| 89051 | <1% | 43 | $1K | |
| 73110 | <1% | 25 | $1K | |
| 87116 | <1% | 170 | $1K | |
| 86787 | <1% | 407 | $1K | |
| 82043 | <1% | 357 | $978.62 | |
| 69210 | <1% | 30 | $937.83 | |
| 86235 | <1% | 34 | $925.16 | |
| 92550 | <1% | 25 | $910.57 | |
| 86849 | <1% | 86 | $890.39 | |
| 97161 | <1% | 14 | $864.99 | |
| 86352 | <1% | 53 | $854.54 | |
| 87075 | <1% | 13 | $824.79 | |
| 92235 | <1% | 12 | $789.48 | |
| X3910 | <1% | 64 | $782.28 | |
| 76514 | <1% | 13 | $679.46 | |
| 83690 | <1% | 42 | $663.93 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 13 | $651.61 |
| 90653 | <1% | 61 | $649.48 | |
| Z7610 | <1% | 64 | $638.16 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 15 | $618.65 |
| 87899 | <1% | 27 | $582.89 | |
| 86039 | <1% | 273 | $564.42 | |
| 88300 | <1% | 12 | $465.83 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 55 | $458.70 |
| 0480 | <1% | 39 | $456.42 | |
| 87206 | <1% | 156 | $410.31 | |
| 84550 | <1% | 58 | $374.87 | |
| 80158 | <1% | 21 | $373.51 | |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 44 | $314.10 |
| 86682 | <1% | 43 | $263.48 | |
| 20610 | <1% | 14 | $260.93 | |
| 82375 | <1% | 14 | $257.72 | |
| 87305 | <1% | 14 | $242.43 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 33 | $238.00 |
| 82785 | <1% | 15 | $220.16 | |
| 84132 | <1% | 20 | $215.46 | |
| 92285 | <1% | 13 | $205.63 | |
| 86225 | <1% | 27 | $189.64 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 104 | $184.07 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | <1% | 15 | $183.33 |
| 82810 | <1% | 14 | $154.17 | |
| 82977 | <1% | 14 | $153.59 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 14 | $134.31 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 42 | $131.88 |
| 86038 | <1% | 12 | $127.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 28 | $117.92 |
| 83520 | <1% | 15 | $97.73 | |
| 82248 | <1% | 15 | $91.91 | |
| 86431 | <1% | 12 | $87.72 | |
| 80321 | <1% | 64 | $72.00 | |
| 86200 | <1% | 14 | $69.73 | |
| 92136 | <1% | 14 | $33.07 | |
| 83921 | <1% | 12 | $30.45 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTAYLOR, JEANNINE (SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Keck Medical Center of Usc | Los Angeles, CA | $36.70M |
| Usc Verdugo Hills Hospital | Glendale, CA | $10.03M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.